NCT01800422View on ClinicalTrials.gov

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2021

Study Completion Date

March 31, 2022

Conditions
Stage IA Breast CancerStage IB Breast CancerStage II Breast Cancer
Interventions
DRUG

telapristone acetate

Given orally

OTHER

placebo

Given orally

PROCEDURE

therapeutic conventional surgery

Undergo surgical resection

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

questionnaire administration

Ancillary studies

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
collaborator

Breast Cancer Research Foundation

OTHER

collaborator

Repros Therapeutics Inc.

INDUSTRY

lead

Northwestern University

OTHER